Other News

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Financial by Comments are Disabled

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call.  Starting on July 17th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: https://app.saytechnologies.com/amarin-2024-q2. This Q&A platform will remain open until 24 hours prior to the start of the earnings call. Shareholders can email support@saytechnologies.com for any support inquiries. Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company’s website at www.amarincorp.com Dial in within the United States: 888-506-0062International dial in: 973-528-0011Access Code: 409616Access to replay: Dial in within the United States: 877-481-4010 International dial in: 919-882-2331  Access Code: 50766A replay of the call will also be available through the Company’s website shortly after the call.  About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.    Availability of Other Information About Amarin  Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.  Amarin Contact Information   Investor & Media Inquiries: Mark Marmur Amarin Corporation plc PR@amarincorp.comInvestor.relations@amarincorp.com

Continue Reading →

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Coronary/Structural Heart by Comments are Disabled

SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035. The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value. Procedures that leverage transseptal delivery include atrial fibrillation ablation, patent foramen ovale (PFO) and atrial septal defect (ASD) repair, percutaneous mitral valve repair, left atrial appendage closure, and percutaneous left ventricular assist device placement, among others. Worldwide revenue from the transseptal access systems market was $941.3 million in 2022, with the global market estimated to expand at a Compound Annual Growth Rate of 7.3%, reaching $2.1 billion by the end of 2033(1). Morph DNA designs enable the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. The DNA name reflects this design, as these tensioning elements appear as a double helix like that in a strand of DNA. This design is intended to enable smooth navigation and prevent “whip,” when the build-up of mechanical forces in the device causes a catheter to suddenly jump from one orientation to another. “All of the biotherapeutic interventions we support for treatment of heart failure, refractory angina, and acute myocardial infarction going forward are expected to utilize this same introducer technology platform,” said Peter Altman, PhD, BioCardia’s President and Chief Executive Officer. “This is an elegant solution to a long-standing technical issue. The solution enhances the level of physician control in our procedures, and BioCardia is working to provide or partner this solution for the roughly five hundred thousand transseptal procedures performed in the United States each year, and for other vascular access markets that can benefit from the advantages our patented solution provides.” About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms. For more information visit: www.BioCardia.com. Forward Looking Statements: This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the Company’s investigational product candidates, the advantages of the Morph DNA design, and the potential transseptal access delivery vascular market for the Morph DNA steerable introducer product Family. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2024, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. (1) Persistence Market Research (2022). “Transseptal Access Systems Market Outlook (2023-2033).” New York, NY. Persistence Market Research Pvt. Ltd.

Continue Reading →

WELL Health Launches its AI-POWERED Co-pilot for Cardiologists powered by HEALWELL AI to Help Improve Detection of Cardiovascular Disease

Coronary/Structural Heart by Comments are Disabled

WELL has launched its new AI-powered physician co-pilot to assist cardiologists in better identifying patients at high risk of cardiovascular disease (“CVD”). WELL is exclusively partnering with HEALWELL AI, a leader in AI enabled disease diagnosis, as an extension of the WELL AI Decision Support (“WAIDS”) product offering.
The co-pilot will be deployed into WELL Diagnostic Centres, Canada’s largest cardiology and medical diagnostic group, providing support and assisting cardiologists in over 40 locations across Ontario.
CVD stands as the leading cause of death globally, accounting for approximately 32% of deaths worldwide in 2019(1), underscoring the critical need for early detection. HEALWELL also expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (“CRO”), BioPharma Services Inc.

VANCOUVER, BC and TORONTO, July 17, 2024 /PRNewswire/ – WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (“WELL” or the “Company”) a digital health company focused on tech-enabling healthcare providers, and its investee company, HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (“HEALWELL”), a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the launch of WELL’s AI-powered co-pilot for cardiologists exclusively powered by HEALWELL AI, aimed at identifying patients at high risk of cardiovascular disease (“CVD”). This significant expansion of WELL’s AI capabilities builds on the success of its second-generation AI-powered physician co-pilot, WELL AI Decision Support (“WAIDS”), developed exclusively in partnership with HEALWELL. This enhancement adds to its existing rare and chronic disease detection abilities and is an extension to the WAIDS offering.
The co-pilot for cardiologists will be deployed in WELL Diagnostics Centres, Canada’s largest cardiology and medical diagnostic group with over 40 locations in Ontario. It will be available to cardiologists within the WELL Diagnostic Centres ecosystem, providing invaluable support in the early detection and management of cardiovascular disease.
Dina Sergi, CEO of WELL Diagnostic Centres, highlighted the tool’s impact, “The integration of HEALWELL’s AI-powered co-pilot for cardiologists into our WELL Diagnostic Centres represents a game-changing advancement. By offering precise risk stratification and actionable insights, this tool enhances their ability to proactively manage cardiovascular health and improve patient care.”
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “The launch of our AI-powered co-pilot for specialists marks a significant milestone in our mission to enhance healthcare through advanced technology. By expanding our AI capabilities to include cardiovascular disease detection, we are equipping cardiologists with enhanced tools and decision support necessary to identify at-risk patients earlier, ultimately improving patient outcomes and reducing healthcare costs. The integration of this tool into WELL’s Diagnostic Centres is particularly important, as it provides us access to Canada’s largest cardiology group. This vast dataset not only assists hundreds of cardiologists within the WELL Diagnostic Centres ecosystem but also allows us to continuously refine and enhance the co-pilot.”
Dr. Paul Kannampuzha, Chief Cardiology Officer of WELL Diagnostic Centres commented. “As a cardiologist, I am encouraged by how AI can help provide improved disease detection and decision support for cardiologists across the country. I believe this technology will help drive improved preventative care and ensure patients don’t fall through the cracks.”
Cardiovascular disease (CVD) is a group of disorders affecting the heart and blood vessels and is the leading cause of death globally, responsible for approximately 32% of deaths worldwide in 2019(1). In Canada, recent estimates suggest that CVD costs about $22 billion per year and is considered the second leading contributor to healthcare costs(2). Identifying patients with worsening cardiovascular conditions earlier is crucial, as cardiovascular disease is the third leading cause of death in Canada.
The global market for pharmaceutical drugs supporting cardiovascular disease was valued at approximately USD 144.1 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% over the next decade, reaching an estimated USD 207.8 billion by 2033 (Precedence Research)(3). HEALWELL expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (CRO), BioPharma Services Inc.
Footnotes:

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
https://link.springer.com/article/10.1007/s41669-021-00257-8
https://www.precedenceresearch.com/cardiovascular-drugs-market

About WELL Health Technologies Corp.
WELL’s mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL’s solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 175 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL’s solutions are focused on specialized markets such as the gastrointestinal market, women’s health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol “WELL” and on the OTC Exchange under the symbol “WHTCF”. To learn more about WELL, please visit: www.well.company.
About HEALWELL AI
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
Forward-Looking Statements
Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things, the deployment of WAIDS at WELL Health Diagnostic Centres, the use of the WAIDS to improve patient care, and the use of AI technology by HEALWELL to drive research and development opportunities related to CVD. Forward-looking statements are often, but not always, identified by words or phrases such as “opportunity”, “potential”, “improve”, “expect”, “intend”, “create” or variations of such words and phrases or statements that certain future conditions, actions, events or results “will”, “may”, “could”, “would”, “should”, “might” or “can” be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL’s control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: the ability of HEALWELL to utilize AI technologies to detect CVD indicators; the ability to collaborate with the pharmaceutical industry for research and development opportunities, HEALWELL’s continued compliance with third party intellectual property rights; HEALWELL’s continued compliance with privacy laws; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL’s business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in HEALWELL’s most recent annual information form dated April 1, 2024, which is available under HEALWELL’s SEDAR+ profile at www.sedarplus.com. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
SOURCE WELL Health Technologies Corp.

Continue Reading →

LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024

Financial by Comments are Disabled

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com. LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.

Continue Reading →

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

Financial by 0 comments

July 16, 2024 06:30 AM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth […]

Continue Reading →

Inari Medical to Announce Second Quarter 2024 Financial Results

Financial by Comments are Disabled

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website. About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. Investor Contact: Marissa BychGilmartin Group LLCIR@inarimedical.com

Continue Reading →

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

Financial by 0 comments

July 16, 2024 09:00 AM Eastern Daylight Time BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has raised a $260 million Series B financing led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management […]

Continue Reading →

Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI

Coronary/Structural Heart by Comments are Disabled

SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced it will host a virtual KOL webinar on Tuesday, July 30, 2024, at 11:00 AM ET. To register for the webinar, click here. The webinar will feature Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. The webinar will also review data from the development of FDY-5301, an investigational product being evaluated by Faraday in minimizing cardiac damage following acute STEMI. The company’s pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301 in anterior STEMI patients undergoing primary percutaneous intervention is now fully enrolled with topline data anticipated in 2H 2025. A live question and answer session will follow the formal presentations. About Cheerag Shirodaria, BSc, MBBS, MD, FRCP, MBA Dr. Cheerag Shirodaria is Chief Development Officer at Caristo Diagnostics and a Cardiologist at Oxford University Hospitals in the UK. He is an interventional cardiologist who is also an expert in cardiac imaging, particularly cardiac MRI (CMR) and coronary CT angiography (CCTA), having completed his doctoral thesis in Oxford on novel vascular imaging techniques using CMR. He was heavily involved in the design and execution of the phase 2 STEMI trial involving FDY-5301 and is a member of the Executive Steering Committee of the IOCYTE-AMI trial. As co-founder and former CEO of Caristo, he has developed and commercialized novel imaging AI imaging tools to predict future cardiometabolic risk. Dr Shirodaria obtained his medical degree from St Bartholomew’s Hospital Medical College, his medical doctorate from the University of Oxford and his MBA from London Business School. About Marc Bonaca, MD, MPH Dr. Marc Bonaca is a cardiologist and vascular medicine specialist serving as executive director of CPC and Director of Vascular Research & Professor of Medicine at the University of Colorado Anschutz. Dr. Bonaca earned his medical degree from the University of Connecticut and his MPH at Harvard. He completed his medical residency, cardiology fellowship, and vascular medicine fellowship at Brigham and Women’s Hospital and a dedicated research fellowship at the TIMI Study Group. He became faculty at BWH and Harvard Medical School and an investigator at TIMI. He directed pharmacovigilance at TIMI and was an investigator on several large outcomes trials including TRA2P-TIMI 50, PEGASUS-TIMI 54, DECLARE-TIMI 58, and REAL TIMI 63B. In 2018, he joined the faculty at the University of Colorado as Professor of Medicine and the William R. Hiatt Endowed Chair in Cardiovascular Research. He is the Executive Director of CPC, an affiliated non-profit Academic Research Organization. At CPC, he has led several clinical trials with CPC as the lead ARO, including VOYAGER PAD, PREVENT HD, and ASPEN, and is leading several ongoing trials, including BRIGHT and EVOLVE MI, a 4000-patient pragmatic multinational acute coronary syndrome trial. Dr. Bonaca’s research focus is on ischemic risk with atherosclerotic vascular disease, risk prediction, and risk modification using pharmacologic and biologic therapies. He has extensive experience designing and conducting large, multicenter randomized clinical trials, and analyzing registries and real-world datasets. His areas of interest include PAD, PVD, and diabetes, with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. He is also investigating the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies. At CPC, he has focused on building a robust faculty and operational group dedicated to high quality, efficient trials leveraging health networks, informatics, and decentralized design. About J. Antonio T. Gutierrez, MD Dr. Antonio Gutierrez’s clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and percutaneous intervention, and vascular medicine. His research interests are focused on peripheral artery disease. He has been involved in multiple clinical trials involving patients with atherosclerotic disease and has published several peer-reviewed articles and reviews. Dr. Gutierrez received his Bachelor of Arts from the College of the Holy Cross in 2000, Doctorate of Medicine from Case Western Reserve University School of Medicine in 2007, and Masters of Health Science in Clinical Research from Duke University School of Medicine in 2012. He completed his residency in Internal Medicine at Duke University Medical Center in 2010 and was appointed Chief Medical Resident of the Durham VA Medical Center in 2011. Dr. Gutierrez completed his General Cardiology and Vascular Medicine Fellowships at Brigham and Women’s Hospital and a Clinical Research Fellowship at the TIMI Study Group. Most recently Dr. Gutierrez matriculated his Interventional Cardiology Fellowship at Duke University Medical Center. Dr. Gutierrez is currently an Assistant Professor of Medicine at Duke University Hospital and Staff Physician at the Durham VA Medical Center. About STEMI Acute STEMI is a leading cause of cardiovascular death and remains a primary cause of the development of heart failure. Standard treatment of a STEMI involves PCI, during which a catheter is inserted into the artery to remove the blockage and restore blood flow. Following a STEMI, one of the critical factors influencing patient outcomes is reperfusion injury, which occurs when the oxygen-rich blood supply returns to the ischemic heart muscle. About FDY-5301 FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. A Phase 2 clinical trial of FDY-5301 in STEMI patients demonstrated that it was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage. Results from that trial — known as Iocyte AMI — were reported in the January 15, 2022, issue of the International Journal of Cardiology. About Faraday Pharmaceuticals, Inc. Faraday Pharmaceuticals® is a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute STEMI. The company was founded by Dr. Mark Roth of the Fred Hutch Cancer Center and is backed by an investor group led by ARCH Venture Partners and Polaris Partners. The company’s lead program, FDY-5301, is in a pivotal Phase 3 trial and is designed to reduce IRI in acute STEMI, a leading cause of death and a primary cause of the development of heart failure. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com or follow the company on LinkedIn. Contact:Brian BlackmanChief Financial Officerbblackman@faradaypharma.com Contact:PJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@lifesciadvisors.com

Continue Reading →

SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography

Coronary/Structural Heart by Comments are Disabled

MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) — HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on the use of coronary computed tomography angiography (coronary CTA) in coronary artery disease (CAD) management and insights on CTA reimbursement at the upcoming 19th Annual Scientific Meeting of SCCT. The annual meeting will take place on July 18-21, 2024 in Washington, D.C. Subset data from the PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) Trial will also be presented. The PRECISE clinical trial data, originally presented in late 2022, confirmed CTA + FFRCT increases diagnostic accuracy, reduces unnecessary testing and offers higher confidence in identifying patients needing treatment versus traditional testing (stress nuclear, stress echo, and invasive coronary angiography). The new subset data analyzes the association between body mass index, testing performance and clinical outcomes in patients with stable chest pain. New insights from the ADVANCE Registry, including analysis on the relationship between risk factors and quantified atherosclerotic burden and differences in plaque quantification in a Japanese patient population will be shared. Along with the significant work HeartFlow has undertaken to develop age and sex specific nomograms, these data will be a pivotal step to better stratify patients and impact treatment decisions going forward. “The critical role of CTA in the diagnosis and management of coronary artery disease continues to drive every decision we make, ensuring the right patients are getting the right care at the right time,” said Campbell Rogers, Chief Medical Officer of HeartFlow. “This year, we are excited to share the latest insights on the importance of quantifying coronary artery plaque, as well as changes in the reimbursement landscape. We are pleased to continue providing robust clinical evidence as to how our products can help health care providers manage their patient’s heart health.” Details of the presentations are as follows: Session: Poster Session 8 – CT in Non-Acute Chest PainTitle: “Association Between Body Mass Index, Testing Performance And Clinical Outcomes In Patients With Stable Chest Pain: Insights From The PRECISE Trial”Date: Friday, July 19, 2024Time: 9:30 – 10:15 AM EDTLocation: Exhibit Hall Session: Poster Session 16 – Plaque ImagingTitle: The Relationship Of Risk Factors And Quantified Atherosclerotic Burden On Coronary Computed Tomographic Angiography – Lessons From The ADVANCE RegistryDate: Saturday, July 20 Time: 9:30 – 10:35 AM EDTLocation: Exhibit Hall Session: Poster Session 16 – Plaque ImagingTitle: Quantitative Differences Between Japanese And Non-Japanese Patients’ Coronary Computed Tomographic Angiography Derived Plaque – Insights From The ADVANCE RegistryDate: Saturday, July 20 Time: 9:30 – 10:35 AM EDTLocation: Exhibit Hall Session: Business Aspects of Cardiac CT – Part TwoTitle: “How clinicians can work with administrators to maximize cardiac CT reimbursement” Presenter: Cara SantilloDate: Thursday, July 18, 2024Time: 4:05 PM – 4:20 PM EDT Location: Liberty N-P Heartflow invites attendees to two sponsored events, including “Women in CT Happy Hour,” which will take place on July 18 from 6:00 PM – 7:00 PM EDT in the 2nd Floor Lobby, and “The Power of HeartFlow AI in the Management of CAD from Diagnosis to Treatment” symposium, which will take place on July 19 from 11:55 AM – 12:45 PM EDT in the Capitol/Congress Room. About HeartFlow, Inc.HeartFlow is transforming precision coronary care with the only AI-powered non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guideline, HeartFlow continues to advance the diagnosis and management of CAD. HeartFlow’s suite of non-invasive technologies includes its FFRCT Analysis, RoadMap™Analysis, and Plaque Analysis. To date, more than 500 peer-reviewed publications have validated our approach and, more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.heartflow.com. Media ContactLinly KuSr. Digital Marketing Managermedia@heartflow.com Investor ContactNick Laudico VP of Business Development and Investor Relationsnlaudico@heartflow.com

Continue Reading →

TeleSpecialists Revolutionizes Stroke Care with Launch of Innovative EMS Integration Service

Neuro by Comments are Disabled

EMS Integration to enhance door-to-needle times and elevate patient outcomes
FORT MYERS, Fla., July 16, 2024 /PRNewswire/ — TeleSpecialists, LLC, the nation’s largest inpatient provider of TeleStroke and TeleNeurology services, launches its EMS Integration service as an enhancement to its current neurology services. This new service will allow TeleSpecialists’ board-certified neurologists to expedite stroke treatment and improve patient outcomes.
TeleSpecialists introduces the EMS Integration service for EMS and local hospitals, to enhance patient care in telestroke and teleneurology. This program enables physicians to interact with EMS teams, and hospitals simultaneously during patient transport. Early teleneurology involvement reduces door-to-needle times by connecting a neurologist on-screen during transit to conduct essential tests. With improved efficiency and collaboration, patients can receive a CT scan immediately upon arrival at the hospital. 
“At TeleSpecialists, we are dedicated to pioneering innovations that enhance patient care. Our EMS Integration service represents a major advancement in our ability to improve patient outcomes, particularly in stroke care,” said Nima Mowzoon, MD, MBA, CEO of TeleSpecialists. “By enabling real-time neurology consultations en route to the hospital, we can significantly expedite treatment times and save more lives. This initiative is a testament to our commitment to leveraging technology to deliver the highest quality care to our communities.”
The introduction of the EMS Integration program emphasizes the organization’s commitment to clinical collaboration and continuous improvement in stroke care. This program aims to establish seamless communication between EMS providers and TeleSpecialists to provide timely and effective care for stroke patients in diverse settings. By integrating EMS into its TeleNeurology processes, the company seeks to optimize the delivery of critical interventions and resources, ultimately improving patient outcomes.
The launch of the EMS Integration program at Oak Hill and Bayonet Point Hospital in Hernando County marks a significant milestone in expanding and enhancing TeleSpecialists’ services. With over 10 years of experience and over one million patients seen, this initiative underscores the company’s commitment to delivering improved outcomes to these communities.
About TeleSpecialists, LLCAs the leader in TeleStroke and TeleNeurology and a reliable provider of exceptional TelePsychiatry services in the US, we lead the industry with unmatched quality, scale, and expertise. We seamlessly integrate cutting-edge technology with compassionate care, always striving to preserve and enhance lives through our commitment to excellence.
SOURCE TeleSpecialists

Continue Reading →
1 … 241 242 243 244 245 … 1,340